More Arovella Therapeutics Limited news
Arovella Therapeutics LimitedASX: ALA

Investor Presentation

Jan 31, 2022 at 11:37 PM EST · Issued by Arovella Therapeutics Limited

Filed with ASX · Jan 31, 2022 at 11:37 PM EST

On 6ix: 6ix.com/news/investor-presentation-292

Arovella Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Arovella Therapeutics Limited on 6ix

In the deck

  • Arovella Therapeutics — Investor Presentation (February 2022)35 slidesFeb 1, 2022

Story so far

  • AGM FY21 PresentationDec 16, 2021
  • GM presentationOct 14, 2021
  • Investor Presentation incorporating iNKT Cell PlatformJun 18, 2021

Earlier from Arovella Therapeutics

  • SPP Offer BookletJan 23, 2022
  • Arovella Completes $4.57M Placement & Launches $1.5M SPPJan 23, 2022
  • AGM FY21 PresentationDec 15, 2021
  • Arovella licences novel monoclonal antibody from MD AndersonDec 12, 2021
  • Chile Ministry of Health Approval Granted for ZolpiMistOct 20, 2021

Later from Arovella Therapeutics

  • Arovella SPP Closed early over subscribedFeb 21, 2022
  • Update - Proposed issue of securities - ALAFeb 28, 2022
  • Application for quotation of securities - ALAMar 16, 2022
  • Arovella Therapeutics: Proposed issue of securities - ALAMar 17, 2022
  • Anagrelide patent for the United StatesApr 5, 2022
All Arovella Therapeutics news releases↗

Follow Arovella Therapeutics into a list and get an email when it puts out news.

Follow Arovella Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer